发明名称 Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B
摘要 This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-²-L-rythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2'-deoxy-²-L-erythro-pentofuranonucleoside has formula (I) wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2'-deoxy-²-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2'-deoxy-²-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.
申请公布号 EP2415776(B1) 申请公布日期 2016.05.25
申请号 EP20100184657 申请日期 1999.08.10
申请人 NOVARTIS AG;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;L'UNIVERSITÉ MONTPELLIER II 发明人 GOSSELIN, GILLES;IMBACH, JEAN-LOUIS;BRYANT, MARTIN L.
分类号 C07H19/06;C07H19/073;A61K31/522;A61K31/70;A61K31/7042;A61K31/7052;A61K31/7064;A61K31/7068;A61K31/7072;A61K31/7076;A61K31/708;A61P31/12;A61P31/20;C07H19/10;C07H19/16;C07H19/173;C07H19/20 主分类号 C07H19/06
代理机构 代理人
主权项
地址